Novo Nordisk to slash U.S. insulin prices, following move by Eli Lilly
The Danish drugmaker will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%.
This archive spans one of the most eventful periods in recent history, from 2017 through 2025. Browse more than 4,100 articles documenting scientific breakthroughs, policy wins, social progress, and human ingenuity from the present era. Each story highlights what people and communities around the world are building, solving, and achieving right now.
The Danish drugmaker will reduce the list price of its NovoLog insulin by 75%, and for Novolin and Levemir by 65%.
Walz’s executive order parallels legislation awaiting a floor vote in the state House to make Minnesota a “trans refuge state.”
For years, Honduras was the only nation in the Americas to have an absolute ban on the sale or use of emergency contraception, also known as morning-after or “Plan B” pills.
Participants made 341 commitments worth nearly $20 billion, including funding for expanding and improving marine protected areas and biodiversity corridors.
The drug, developed by researchers at the U.K.’s University of East Anglia, increases survival rates by 50% without the need for surgery or chemotherapy.
India’s largest renewable power generation company has announced that it successfully commissioned a 700 megawatt solar-wind hybrid project in the northern state of Rajasthan.
Among the new professions available to female domestic workers are driver, personal care worker, home tailor, home manager, private tutor and home farmer.
In 2006, the U.S. EPA banned the agricultural use of lindane, linked to anemia, lung cancer, and lymphoma. In 2010, it began to phase out endosulfan, which experts say may damage the liver and kidneys.
The expungement is the latest byproduct of the constitutional amendment approved by Missouri voters, which legalized pot for adults and cleared the way for Missourians to have their records cleared.
Gene therapy has cured 19-month-old Teddi Shaw of metachromatic leukodystrophy, making her the first NHS patient treated for this rare, fatal nervous system disease. After a single infusion of Libmeldy at Royal Manchester Children’s Hospital, she’s now running around, chattering away, and showing no signs of the illness that typically kills children before age eight. The treatment works by correcting a faulty gene in the child’s own stem cells, eliminating the disease at its root rather than managing it. Her family’s joy is tempered by grief — Teddi’s older sister was diagnosed too late for the therapy to help, fueling calls for newborn screening. It’s a glimpse of medicine’s next era: one-time cures for inherited conditions, if access and early detection can keep pace.